Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced the completion of patient enrollment in two randomized, double-masked, Phase 3 clinical trials evaluating VEGF Trap-Eye in the treatment of the neovascular form of age-related macular degeneration (wet AMD).
… positive twelve-month primary analysis results from the Phase II RADICAL study (Reduced Fluence Visudyne Anti-VEGF-Dexamethasone In Combination for AMD Lesions) in patients with wet age-related macular degeneration (”wet AMD”). …
Three additional presentations reported results from animal models of wet age-related macular degeneration (wet AMD). In one study, Resolvyx and its collaborators demonstrated for the first time that topical administration of the …
Dan Brown asked: The two important types of age related macular degeneration are wet AMD and dry AMD. The forms can attack any one or both of the eyes. A.
Dan Brown asked: The two important types of age related macular degeneration are wet AMD and dry AMD. The forms …
